Cargando…
Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague
Plague pandemics and outbreaks have killed millions of people during the history of humankind. The disease, caused by the bacteria Yersinia pestis, is currently treated effectively with antibiotics. However, in the case of multidrug-resistant (MDR) bacteria, alternative treatments are required. Bact...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024586/ https://www.ncbi.nlm.nih.gov/pubmed/35458417 http://dx.doi.org/10.3390/v14040688 |
_version_ | 1784690635253481472 |
---|---|
author | Vagima, Yaron Gur, David Aftalion, Moshe Moses, Sarit Levy, Yinon Makovitzki, Arik Holtzman, Tzvi Oren, Ziv Segula, Yaniv Fatelevich, Ella Tidhar, Avital Zauberman, Ayelet Rotem, Shahar Mamroud, Emanuelle Steinberger-Levy, Ida |
author_facet | Vagima, Yaron Gur, David Aftalion, Moshe Moses, Sarit Levy, Yinon Makovitzki, Arik Holtzman, Tzvi Oren, Ziv Segula, Yaniv Fatelevich, Ella Tidhar, Avital Zauberman, Ayelet Rotem, Shahar Mamroud, Emanuelle Steinberger-Levy, Ida |
author_sort | Vagima, Yaron |
collection | PubMed |
description | Plague pandemics and outbreaks have killed millions of people during the history of humankind. The disease, caused by the bacteria Yersinia pestis, is currently treated effectively with antibiotics. However, in the case of multidrug-resistant (MDR) bacteria, alternative treatments are required. Bacteriophage (phage) therapy has shown efficient antibacterial activity in various experimental animal models and in human patients infected with different MDR pathogens. Here, we evaluated the efficiency of фA1122 and PST phage therapy, alone or in combination with second-line antibiotics, using a well-established mouse model of pneumonic plague. Phage treatment significantly delayed mortality and limited bacterial proliferation in the lungs. However, the treatment did not prevent bacteremia, suggesting that phage efficiency may decrease in the circulation. Indeed, in vitro phage proliferation assays indicated that blood exerts inhibitory effects on lytic activity, which may be the major cause of treatment inefficiency. Combining phage therapy and second-line ceftriaxone treatment, which are individually insufficient, provided protection that led to the survival of all infected animals—a synergistic protective effect that represents a proof of concept for efficient combinatorial therapy in an emergency event of a plague outbreak involving MDR Y. pestis strains. |
format | Online Article Text |
id | pubmed-9024586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90245862022-04-23 Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague Vagima, Yaron Gur, David Aftalion, Moshe Moses, Sarit Levy, Yinon Makovitzki, Arik Holtzman, Tzvi Oren, Ziv Segula, Yaniv Fatelevich, Ella Tidhar, Avital Zauberman, Ayelet Rotem, Shahar Mamroud, Emanuelle Steinberger-Levy, Ida Viruses Article Plague pandemics and outbreaks have killed millions of people during the history of humankind. The disease, caused by the bacteria Yersinia pestis, is currently treated effectively with antibiotics. However, in the case of multidrug-resistant (MDR) bacteria, alternative treatments are required. Bacteriophage (phage) therapy has shown efficient antibacterial activity in various experimental animal models and in human patients infected with different MDR pathogens. Here, we evaluated the efficiency of фA1122 and PST phage therapy, alone or in combination with second-line antibiotics, using a well-established mouse model of pneumonic plague. Phage treatment significantly delayed mortality and limited bacterial proliferation in the lungs. However, the treatment did not prevent bacteremia, suggesting that phage efficiency may decrease in the circulation. Indeed, in vitro phage proliferation assays indicated that blood exerts inhibitory effects on lytic activity, which may be the major cause of treatment inefficiency. Combining phage therapy and second-line ceftriaxone treatment, which are individually insufficient, provided protection that led to the survival of all infected animals—a synergistic protective effect that represents a proof of concept for efficient combinatorial therapy in an emergency event of a plague outbreak involving MDR Y. pestis strains. MDPI 2022-03-26 /pmc/articles/PMC9024586/ /pubmed/35458417 http://dx.doi.org/10.3390/v14040688 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vagima, Yaron Gur, David Aftalion, Moshe Moses, Sarit Levy, Yinon Makovitzki, Arik Holtzman, Tzvi Oren, Ziv Segula, Yaniv Fatelevich, Ella Tidhar, Avital Zauberman, Ayelet Rotem, Shahar Mamroud, Emanuelle Steinberger-Levy, Ida Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague |
title | Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague |
title_full | Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague |
title_fullStr | Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague |
title_full_unstemmed | Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague |
title_short | Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague |
title_sort | phage therapy potentiates second-line antibiotic treatment against pneumonic plague |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024586/ https://www.ncbi.nlm.nih.gov/pubmed/35458417 http://dx.doi.org/10.3390/v14040688 |
work_keys_str_mv | AT vagimayaron phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT gurdavid phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT aftalionmoshe phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT mosessarit phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT levyyinon phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT makovitzkiarik phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT holtzmantzvi phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT orenziv phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT segulayaniv phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT fatelevichella phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT tidharavital phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT zaubermanayelet phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT rotemshahar phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT mamroudemanuelle phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague AT steinbergerlevyida phagetherapypotentiatessecondlineantibiotictreatmentagainstpneumonicplague |